196 related articles for article (PubMed ID: 37438497)
1. Personalized cancer vaccines pass first major clinical test.
Dolgin E
Nat Rev Drug Discov; 2023 Aug; 22(8):607-609. PubMed ID: 37438497
[No Abstract] [Full Text] [Related]
2. Personalized Cancer Vaccines Advance in the Clinic.
Schmidt C
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29095978
[No Abstract] [Full Text] [Related]
3. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
4. Neoantigen Vaccines Pass the Immunogenicity Test.
Linette GP; Carreno BM
Trends Mol Med; 2017 Oct; 23(10):869-871. PubMed ID: 28867556
[TBL] [Abstract][Full Text] [Related]
5. Identification of personalized cancer neoantigens with HANSolo.
Cattaneo CM
Nat Rev Cancer; 2023 Dec; 23(12):800. PubMed ID: 37704741
[No Abstract] [Full Text] [Related]
6. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
7. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
8. Vaccine immunotherapy for cancer.
Bridgewater J; Collins M
Mol Cell Biol Hum Dis Ser; 1995; 5():140-56. PubMed ID: 9532565
[No Abstract] [Full Text] [Related]
9. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
10. Rethinking therapeutic cancer vaccines.
Nat Rev Drug Discov; 2009 Sep; 8(9):685-6. PubMed ID: 19721436
[No Abstract] [Full Text] [Related]
11. Comments on therapeutic cancer vaccines.
Vonka V
Immunotherapy; 2012 Feb; 4(2):133-5. PubMed ID: 22339454
[No Abstract] [Full Text] [Related]
12. A New Generation of Vaccines in the Age of Immunotherapy.
Addeo A; Friedlaender A; Giovannetti E; Russo A; de Miguel-Perez D; Arrieta O; Cardona AF; Rolfo C
Curr Oncol Rep; 2021 Nov; 23(12):137. PubMed ID: 34735649
[TBL] [Abstract][Full Text] [Related]
13. Prospect and progress of personalized peptide vaccinations for advanced cancers.
Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy with MAGE antigens.
Coulie PG
Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
[No Abstract] [Full Text] [Related]
15. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
Kim CG; Sang YB; Lee JH; Chon HJ
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360800
[TBL] [Abstract][Full Text] [Related]
16. Challenges for cancer vaccine development.
Tabi Z; Man S
Adv Drug Deliv Rev; 2006 Oct; 58(8):902-15. PubMed ID: 16979786
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines based on the identification of genes encoding cancer regression antigens.
Rosenberg SA
Immunol Today; 1997 Apr; 18(4):175-82. PubMed ID: 9136454
[No Abstract] [Full Text] [Related]
18. Cancer vaccines: pessimism in check.
Mocellin S; Mandruzzato S; Bronte V; Marincola FM
Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242
[No Abstract] [Full Text] [Related]
19. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
20. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
